Time: Thursday, February 8, 2007 at 4 p.m. CET. Telephone number: +46 8 505 201 10 Conference name: Vitrolife
Vitrolife participants: Magnus Nilsson, CEO Anna Ahlberg, CFO
The press release for Vitrolife's report on operations 2006 will be released in good time before 4 p.m. CET on February 8.
Before the conference call, slides will be available at the company web page, www.vitrolife.com, under the section Investors/News (the Swedish page).
A recorded version of the presentation will be available for seven days on number +46 8 505 203 33, access code 736804.
Queries should be addressed to: Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media to enable the use of stem cells for therapeutic purposes.
Vitrolife today has approximately 120 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The Vitrolife share is listed on the Stockholm Stock Exchange's Nordic Small Cap list.
This information was brought to you by Waymaker http://www.waymaker.net
© 2007 Business Wire
